Hepion Historical Financial Ratios
HEPA Stock | USD 0.63 0.02 3.28% |
Hepion Pharmaceuticals is recently reporting on over 98 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 1.86 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Hepion Pharmaceuticals financial condition quickly.
Hepion |
About Hepion Financial Ratios Analysis
Hepion PharmaceuticalsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Hepion Pharmaceuticals investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Hepion financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Hepion Pharmaceuticals history.
Hepion Pharmaceuticals Financial Ratios Chart
Add Fundamental
Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Hepion Pharmaceuticals' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Hepion Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.At present, Hepion Pharmaceuticals' PTB Ratio is projected to increase significantly based on the last few years of reporting. The current year's Average Payables is expected to grow to about 2.6 M, whereas Book Value Per Share is forecasted to decline to 1.74.
2021 | 2022 | 2023 | 2024 (projected) | Net Debt To EBITDA | 3.0 | 1.17 | 0.3 | 0.28 | Intangibles To Total Assets | 0.0489 | 0.053 | 0.0609 | 0.0578 |
Hepion Pharmaceuticals fundamentals Correlations
Click cells to compare fundamentals
Hepion Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Hepion Pharmaceuticals fundamentals Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Ptb Ratio | 0.7 | 0.52 | 0.86 | 0.46 | 1.77 | 1.86 | |
Book Value Per Share | 152.86 | 83.74 | 26.46 | 13.08 | 1.83 | 1.74 | |
Free Cash Flow Yield | (0.7) | (0.77) | (0.39) | (1.53) | (3.18) | (3.02) | |
Operating Cash Flow Per Share | (74.05) | (33.41) | (8.88) | (9.17) | (10.3) | (10.81) | |
Pb Ratio | 0.7 | 0.52 | 0.86 | 0.46 | 1.77 | 1.86 | |
Free Cash Flow Per Share | (74.55) | (33.59) | (8.92) | (9.18) | (10.3) | (10.82) | |
Roic | (0.43) | (0.49) | (0.33) | (0.85) | (6.6) | (6.27) | |
Net Income Per Share | (68.88) | (42.06) | (9.31) | (11.07) | (12.32) | (12.94) | |
Payables Turnover | 0.0544 | 0.009272 | 0.0352 | 0.0291 | 0.0286 | 0.0188 | |
Cash Per Share | 136.28 | 84.17 | 25.99 | 13.43 | 3.72 | 3.54 | |
Pocfratio | (1.45) | (1.31) | (2.57) | (0.65) | (0.31) | (0.33) | |
Interest Coverage | (14.0) | (645.11) | (3.4K) | (4.5K) | (5.1K) | (4.9K) | |
Pfcf Ratio | (1.44) | (1.3) | (2.56) | (0.65) | (0.31) | (0.33) | |
Days Payables Outstanding | 6.7K | 39.4K | 10.4K | 12.6K | 12.8K | 12.1K | |
Income Quality | 1.07 | 0.79 | 0.95 | 0.83 | 0.84 | 0.66 | |
Roe | (0.45) | (0.5) | (0.35) | (0.85) | (6.72) | (6.38) | |
Ev To Operating Cash Flow | 0.29 | 1.16 | 0.35 | 0.81 | 0.0419 | 0.0439 | |
Pe Ratio | (1.56) | (1.04) | (2.45) | (0.54) | (0.26) | (0.28) | |
Return On Tangible Assets | (0.45) | (0.47) | (0.33) | (0.74) | (2.7) | (2.84) | |
Ev To Free Cash Flow | 0.28 | 1.16 | 0.35 | 0.81 | 0.0418 | 0.0439 | |
Earnings Yield | (0.64) | (0.96) | (0.41) | (1.85) | (3.8) | (3.61) | |
Intangibles To Total Assets | 0.25 | 0.1 | 0.0489 | 0.053 | 0.0609 | 0.0578 | |
Net Debt To E B I T D A | 1.69 | 1.99 | 3.0 | 1.17 | 0.3 | 0.28 | |
Current Ratio | 8.94 | 9.15 | 11.88 | 7.16 | 3.31 | 3.82 | |
Tangible Book Value Per Share | 103.32 | 73.28 | 25.02 | 12.24 | 1.83 | 1.93 | |
Graham Number | 486.74 | 281.52 | 74.45 | 57.08 | 22.55 | 21.42 | |
Shareholders Equity Per Share | 152.86 | 83.74 | 26.46 | 13.08 | 1.83 | 1.74 | |
Debt To Equity | 0.0171 | 0.0113 | 0.002867 | 0.001075 | 0.0159 | 0.0167 | |
Graham Net Net | 87.39 | 67.37 | 22.99 | 10.7 | 1.0 | 1.05 | |
Interest Debt Per Share | 8.04 | 1.01 | 0.0784 | 0.0167 | 0.0316 | 0.03 | |
Debt To Assets | 0.0129 | 0.009382 | 0.002575 | 8.9E-4 | 0.006406 | 0.006086 | |
Enterprise Value Over E B I T D A | 0.28 | 0.93 | 0.36 | 0.65 | 0.0347 | 0.0365 | |
Short Term Coverage Ratios | (28.37) | (57.77) | (117.1) | (652.09) | (352.75) | (370.38) | |
Price Earnings Ratio | (1.56) | (1.04) | (2.45) | (0.54) | (0.26) | (0.28) | |
Price Book Value Ratio | 0.7 | 0.52 | 0.86 | 0.46 | 1.77 | 1.86 | |
Price Earnings To Growth Ratio | 0.0167 | 0.0267 | 0.0315 | (0.0287) | (0.0233) | (0.0221) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Hepion Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hepion Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hepion Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hepion Pharmaceuticals Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hepion Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For information on how to trade Hepion Stock refer to our How to Trade Hepion Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hepion Pharmaceuticals. If investors know Hepion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hepion Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.40) | Return On Assets (0.93) | Return On Equity (1.90) |
The market value of Hepion Pharmaceuticals is measured differently than its book value, which is the value of Hepion that is recorded on the company's balance sheet. Investors also form their own opinion of Hepion Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Hepion Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hepion Pharmaceuticals' market value can be influenced by many factors that don't directly affect Hepion Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hepion Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hepion Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hepion Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.